TransForm Appoints Duncan Higgons as Chief Commercial Officer.Business Editors LEXINGTON, Mass.--(BUSINESS WIRE)--Jan. 9, 2003 TransForm Pharmaceuticals Inc. (TransForm) announced today that Duncan Higgons has joined the company in the newly created position of Chief Commercial Officer. In this role, Mr. Higgons will be responsible for the continued development and expansion of all commercialization initiatives at TransForm including business development, corporate strategy and product development. Mr. Higgons will report to Norman C. Selby, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of TransForm. "TransForm is growing rapidly, and has an increasing number of significant value creation opportunities leveraging our novel platform technologies and our expanding proprietary product efforts. Duncan has a broad range of experience in both business and product development, and is a great addition to the TransForm management team", said Mr. Selby. "We're delighted to welcome someone of his caliber, and look forward to his leadership in helping build TransForm into a distinctive pharmaceutical company." Mr. Higgons is an industry leader with over 20 years of commercial experience in pharmaceuticals and biotechnology. Most recently, he was Senior Vice President, Business Development and Marketing for Alkermes, Inc. where he managed a broad range of functions including new product identification, portfolio planning, and business development. He established a track record of successful negotiations while at Alkermes, including publicly announced deals with Johnson & Johnson, Ortho Biotech, Janssen, Genentech, Lilly, Glaxo Smith Kline, Serono, Alza and Schering-Plough. In addition, he identified new internal products for development, several of which are in advanced clinical trials. Prior to Alkermes Mr. Higgons held senior management positions at Eli Lilly Eli Lilly can refer to:
Mr. Higgons is a graduate of King's College, University of King's College, University of: see Dalhousie Univ. London and received an MBA MBA abbr. Master of Business Administration Noun 1. MBA - a master's degree in business Master in Business, Master in Business Administration from London Business School Around 800 degree students, from 70 countries, graduate from the school each year. Over 80 percent of students, and over 70 percent of faculty, come from outside the UK. A further 6,000 executives attend the school executive education programmes each year. where he was selected by the faculty for an Exchange Scholarship to the Wharton Graduate School at the University of Pennsylvania (body, education) University of Pennsylvania - The home of ENIAC and Machiavelli. http://upenn.edu/. Address: Philadelphia, PA, USA. . "This is a very exciting time to join the TransForm team given their progress and demonstrated success," commented Duncan Higgons. "In my new job I hope to help TransForm leverage their powerful platform technologies and the quality of their scientists to do significant deals with pharmaceutical companies and advance products that create significant value and accelerate the company's growth," concluded Higgons. About TransForm TransForm Pharmaceuticals is reinventing the pharmaceutical industry's approach to form and formulation, with a novel set of high-throughput, automated platform technologies, powered by state-of-the-art informatics and a scientific and managerial team with deep experience in pharmaceuticals. It uses these capabilities to optimize drug form and/or formulations, and increase the clinical and commercial value of pharmaceutical products, across the entire pharmaceutical value chain. In R&D, TransForm is working with partners such as Alza Corporation and Eli Lilly and Co., to help them make better candidate selection decisions, and reduces attrition and development time and cost. For later stage and marketed products, TransForm can help partners enhance product life cycle management by rapidly discovering novel forms and/or formulations to potentially improve bioavailability bioavailability /bio·avail·a·bil·i·ty/ (bi?o-ah-val?ah-bil´i-te) the degree to which a drug or other substance becomes available to the target tissue after administration. bi·o·a·vail·a·bil·i·ty n. , broaden intellectual property protection and enable new dosage forms and/or combination products. TransForm is also using these capabilities to develop its own proprietary product portfolio. TransForm, founded in late 1999 with initial technology from Millennium Pharmaceuticals (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :MLNM), is a privately held company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. located in Lexington, MA. For more information visit our website at www.transformpharma.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion